Amicogen Inc (092040) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of Amicogen Inc stock KRW 969, price KRW 929, upside +4.3%, quality 25 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Amicogen Inc
092040 · KQThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.
How to read this chart
60‑month range 822.00 KRW – 20,964 KRW · fair‑value band 726.80 KRW – 1,211 KRW · the 929.00 KRW price screens below the 969.07 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.
Every Wednesday you see whether Amicogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food.
Show moreShow less
It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products.
In addition, the company offers oral incurable and rare disease treatments, as well as manufactures and sells of pharmaceutical raw materials, animal drugs, human drugs, etc. The company was incorporated in 2000 and is headquartered in Jinju-Si, South Korea.
Stock analysis
Amicogen Inc (092040) currently trades at 929.00 KRW, while our estimate is 969.07 KRW, so the stock looks roughly fairly valued today (gap 4.1%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 726.80 KRW (bear) to 1,211 KRW (bull), the price of 929.00 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Amicogen Inc reported revenue of 42.0B KRW in FY2025 versus 125B KRW in FY2021, a compound −23.9%/yr. Reported net income was −30.0B KRW in FY2025.
Key figures
Market cap 65.2B KRW (≈ $48.9M) Micro · P/S ratio 1.50 · EPS (TTM) −273.85 KRW · Net margin −41.3% · Return on equity −16.8% · Return on assets (EBIT) −2.9% (5-year average) · Operating margin −30.1% · Revenue (TTM) 46.7B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).
What moves the price
The share trades about 69% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 4%, 092040 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 092040, get fair value alerts →
Compare Amicogen Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Stock screener with 62 metrics
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.48 | $113.53 | +36% | vs 092040 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.90 | ¥52.43 | +12% | vs 092040 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,872 | ₹1,983 | +6% | vs 092040 |
| Haleon plc HLN | $9.05 | $8.47 | −6% | vs 092040 |
| Merck KGaA MRK | €149.50 | €108.83 | −27% | vs 092040 |
| Galderma Group GALD | CHF 187.55 | CHF 112.46 | −40% | vs 092040 |
| Takeda Pharmaceutical Company TAK | $21.64 | $11.23 | −48% | vs 092040 |
| Sandoz Group SDZ | CHF 81.50 | CHF 40.91 | −50% | vs 092040 |
| Teva Pharmaceutical Industries Limited TEVA | $42.62 | $20.74 | −51% | vs 092040 |
| Divi's Laboratories Limited DIVISLAB | ₹11,049 | ₹1,567 | −86% | vs 092040 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Amicogen Inc (092040) overvalued or undervalued?
What is the fair value of 092040?
What is the quality score of 092040?
What is the price target for Amicogen Inc (092040)?
What is the Amicogen Inc stock forecast for 2026?
What is the revenue of Amicogen Inc (092040)?
What is the intrinsic value of Amicogen Inc (092040)?
Is Amicogen Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 092040?
How much is Amicogen Inc worth?
What do the bullish and bearish scenarios say about 092040?
How solid is the balance sheet of Amicogen Inc (092040)?
How far is 092040 from its 52-week high?
Which stocks are comparable to Amicogen Inc?
Is Amicogen Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Amicogen Inc (092040)?
What should I pay attention to with Amicogen Inc right now?
Key figures of Amicogen Inc
How large is the market capitalisation of Amicogen Inc (092040)?
What is the P/S ratio of Amicogen Inc (092040)?
What are the earnings per share of Amicogen Inc (092040)?
What is the net margin of Amicogen Inc (092040)?
What is the return on equity of Amicogen Inc (092040)?
What is the EBIT return on assets of Amicogen Inc (092040)?
What is the operating margin of Amicogen Inc (092040)?
How fast is revenue growing at Amicogen Inc (092040)?
How fast are earnings growing at Amicogen Inc (092040)?
How much free cash flow does Amicogen Inc (092040) generate?
How much net debt does Amicogen Inc (092040) carry?
Watch Amicogen Inc in the live analysis
One click puts Amicogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.